ALSO NOTED: New drug approval lags in 2007; Velcade boosts Millenium Pharma's outlook;

> The FDA has suffered no small amount of criticism recently, and, according to the Wall Street Journal, the agency's efforts to protect itself from naysayers have contributed significantly to he low number of new drugs approved in 2007. Report

> Strong Velcade sales prompted Millennium Pharmaceuticals to boost its year-end profits forecast to $40 million to $45 million, up from $20 million to $30 million. Report

> The FDA gave a tentative nod to Cipla's generic version of Bristol-Myers Squibb's pediatric HIV drug Zerit. Report

> Maryland-based Vanda Pharmaceuticals said it would two days ago--but now it says it won't offer $100 million in senior notes. Report

> India's Flamingo Pharmaceuticals says it plans to introduce 20 new generics in that country over the next six months, and it's beefing up its distribution network to handle the new business. Report

And Finally... WHO officials are calling on drug companies to help fight a co-epidemic of HIV and drug-resistant TB that's sweeping sub-Saharan Africa. Report